Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2016

View Archived Issues

Heptares updates on muscarinic M1 receptor agonist programs for cognitive impairment

Enrollment begins in phase Ib study of CV-MG01 in myasthenia gravis

FDA grants orphan drug designation to eltoprazine

Cidara Therapeutics's CD101 IV wins FDA orphan drug status

Cocrystal inlicenses CRISPR/Cas9 technologies

Synlogic and AbbVie enter IBD collaboration

AbbVie reports topline results from phase III elagolix trial in endometriosis

FDA lifts partial clinical hold on vesigenurtucel-L

UCB and Baylor College of Medicine enter strategic neurodegeneration research alliance

Lundbeck recaps progress of fourth quarter 2015

Astellas Pharma completes tender offer for Ocata Therapeutics

SymBio and Teikyo Heisei University collaborate to develop TTR1 therapeutic anticancer drug

Patient with B-cell lymphoma in remission following treatment with OXS-1550

Shanghai Allist Pharmaceutical presents EGFR inhibitors

Innov17 patents retinoid-related orphan receptor ligands

February 12: Thomson Reuters Drug News Publication Holiday

GlaxoSmithKline introduces Lp-PLA2 inhibitors

Boehringer Ingelheim Pharma divulges cytochrome P450 inhibitors

Beta Pharma patent describes CDK4 and 6 inhibitors

Almirall completes acquisition of ThermiGen

Biogen launches USD 20 million challenge for Target ALS

FDA accepts KP-201/APAP NDA, grants priority review

Small peptide IL-1beta receptor antagonist from Serodus delays diabetes onset in vivo

Somatostatin sst2 receptor antagonist ameliorates hypoglycemia after recurrent hypoglycemic events

Resolve Therapeutics reports positive data from SLE study

TransCelerate BioPharma launches BioCelerate subsidiary

Mylan makes offer to acquire Meda

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.